Classes
DEA Class; Rx
Common Brand Names; Lunesta
- Sedative/Hypnotics
Description
Short-acting non-benzodiazepine hypnotic.
Rapid onset and relatively short half-life reduces ‘hangover’ effects; does not cause early-AM awakening.
Used for treatment of insomnia.
Indications
Indicated for the treatment of insomnia.
Contraindications
Documented hypersensitivity
Patients who have experienced complex sleep behaviors after receiving therapy
Adverse Effects
- Headache (13-21%)
- Unpleasant taste (17-34% in non-elderly)
- Abnormal dreams (elderly)
- Accidental injury (elderly)
- Diarrhea
- Dizziness
- Dry mouth
- Dyspepsia
- Nervousness
- Neuralgia
- Pain
- Pruritus
- Rash (in non-elderly)
- Somnolence
- Unpleasant taste (elderly)
- UTI
- Agitation
- Alopecia
- Angioedema
- Asthma
- Anorexia
- Cystitis
- Dysphagia
- Fever
- Epistaxis
- Hypertension
- Hostility
- Hypercholesterolemia
- Hypokalemia
Warnings
Take immediately before going to bed – taking earlier may cause memory loss, hallucinations, dizziness, lightheadedness
Can impair daytime function in some patients at the higher doses (2 mg or 3 mg), even when used as prescribed; monitor for next day next-day psychomotor impairment
Take only when able to have a full night of sleep (7-8 hr); coadministration with other sedative-hypnotics at bedtime or taking eszopiclone the middle of the night is not recommended because of risk for next-day psychomotor impairment
May cause CNS depression and impair physical and mental abilities
May worsen clinical depression
Use minimum dose that will effectively treat patient; write prescription for smallest quantity consistent with good patient care
May cause abnormal thinking & bizarre behavior
May impair ability to drive or operate heavy machinery
Caution in history of drug or substance abuse, respiratory diseases, hepatic impairment
Amnesia may occur
Failure of sleep disturbance to resolve after 7-10 days may indicate psychiatric and/or medical illness
Abrupt discontinuation or rapid dose decreases may lead to withdrawal symptoms
Therapy can cause drowsiness and a decreased level of consciousness; patients, particularly the elderly, are at higher risk of falls
Pregnancy and Lactation
Available pharmacovigilance data with use in pregnant women are insufficient to identify drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes
There are no data on prescence in either human or animal milk, effects on breastfed infant, or on milk production
Maximum Dosage
3 mg/day PO.
2 mg/day PO.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
How supplied
Eszopiclone
tablet: Schedule IV
- 1mg
- 2mg
- 3mg